Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-994 multiple rising oral dose study in adults with narcolepsy
NL-OMON51104Phase 2Active, not recruiting
- Sponsor
- Takeda
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of firazorexton in narcolepsy, narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2) (10 arms), sponsored by Takeda. Primary endpoints: Number of subjects with at least 1 treatment-emergent adverse event, Number of subjects with at least 1 markedly abnormal post-dose laboratory value and 3 more. Started Jul 2021; status: active, not recruiting.
02
Drugs
firazorexton
03
Conditions
narcolepsynarcolepsy type 1 (NT1)narcolepsy type 2 (NT2)
Beyond the preview
Go deeper on NL-OMON51104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51104.